Networks of treatment comparisons for primary outcomes of SLE agents in patients with SLE. The size of the nodes (blue circles) corresponds to the number.

Slides:

Advertisements

Similar presentations

Treatment of Vasculitis: immunesuppressives and biologics

Advertisements

Tuesday Clinical Case Conference Zae Kim. Therapy of ANCA-Associated Small Vessel Vasculitis.

Mechanism and New. Lupus Erythematosus - Medication NSAIDs may be used for musculoskeletal and mild systemic complaints, although ibuprofen.

Treatment of LN An European perspective Frédéric A. HOUSSIAU Department of Rheumatology Cliniques universitaires Saint-Luc LOUVAIN Medical School XXXV.

Anti-rheumatic Drugs In Pregnancy And Breastfeeding

Randomized Controlled Trials of Methotrexate & Mycophenolate in MG

Algorithm for diagnosis and initial therapy of systemic lupus erythematosus (SLE). For guidelines on management of lupus and lupus nephritis, see BH Hahn.

Management of Myositis-Related Interstitial Lung Disease

Effects of MMF treatment in patients with SLE

Calcineurin Inhibitor-Related Cholestasis Complicating Lung Transplantation Takahiro Oto, MD, Mikio Okazaki, MD, Ken Takata, MD, Moritoki Egi, MD, Masaomi.

EULAR Lupus Nephritis Trials Network Study Group 2017

Nat. Rev. Nephrol. doi: /nrneph

Anifrolumab inhibits type I interferon (IFN)-induced IFN-stimulated response element (ISRE) signalling. Anifrolumab inhibits type I interferon (IFN)-induced.

Nat. Rev. Nephrol. doi: /nrneph

Time between systemic lupus erythematosus (SLE) and haematological malignancy diagnoses. Time between systemic lupus erythematosus (SLE) and haematological.

Disease activity over time in autoantibody-positive patients treated with belimumab. Disease activity over time in autoantibody-positive patients treated.

Idiopathic Inflammatory Myopathies: Current Trends in Pathogenesis, Clinical Features, and Up-to-Date Treatment Recommendations Floranne C. Ernste, MD,

Survival in chronic hypersensitivity pneumonitis (CHP) patients receiving immunosuppressive therapy. a) 5-year survival based on use of immunosuppressive.

Membranous nephropathy: When and how to treat

Time course for laboratory parameters of a patient with systemic lupus erythematosus prior and during bortezomib therapy (arrow). Time course for laboratory.

Fig. 2 TLR8 is aberrantly expressed on pDCs from SSc patients.

Nat. Rev. Rheumatol. doi: /nrrheum

Correlation between disease activity and phospho-H2AX levels at G0/G1, S and G2 cell-cycle phases in primary CD3+ T cells and monocytes from patients with.

Fnu Nutan, Alex G. Ortega-Loayza

Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials Suetonia C. Palmer,

Leflunomide as adjuvant treatment of dermatomyositis

EULAR Lupus Nephritis Trials Network Study Group

Mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) score at the last.

Optimizing Outcomes for Patients With Systemic Lupus Erythematosus: Key Considerations.

Figure 2 Proposed approach to treating myositis-associated interstitial lung disease Figure 2 | Proposed approach to treating myositis-associated interstitial.

Consolidated Standards of Reporting Trials diagram.

Cardiac Transplantation in Pediatric Patients: Fifteen-Year Experience of a Single Center Jan Groetzner, MD, Bruno Reichart, MD, Ulrich Roemer, MD, Stefanie.

Current induction and maintenance treatment choices for proliferative lupus nephritis. Current induction and maintenance treatment choices for proliferative.

Serum osteopontin (OPN) levels in population-based controls and in cases with SLE. Serum levels of OPN, determined by ELISA, were significantly higher.

The pattern of alteration of HCQ, prednisolone and/or ISS drugs by physicians in a patient with a history of major organ involvement from their SLE (renal.

Representative ultrasound images of patients with SLE

No difference in T-cell response between SLE patients and healthy controls upon superantigen stimulation. No difference in T-cell response between SLE.

Mean (SD) AMG 557 serum concentration–time profiles following single-ascending dose (SAD) (A) and multiple-ascending dose (MAD) (B) administration AMG.

Receiver operating curve of soluble C3, C4, antibodies to double-stranded DNA (anti-dsDNA) compared with complement C4d levels on erythrocytes (EC4d) and.

Longitudinal changes in serum G3BP concentrations and SLEDAI in 15 patients with SLE. Each plot represents one patient. Longitudinal changes in serum G3BP.

Timelines used to identify symptoms recorded in the 5 years before SLE diagnosis taking into account data censoring. Timelines used to identify symptoms.

Study schemas. Study schemas. Upper panel: single-ascending dose study. Subjects with mild, stable systemic lupus erythematosus (SLE) were randomised to.

Anifrolumab does not elicit antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) activity. Anifrolumab does.

Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.

Correlation between frequency of Th17 cells and disease activity or amount of proteinuria in patients with systemic lupus erythematosus (SLE). Correlation.

Correlation between mean Safety of Estrogens in Lupus Erythematosus National Assessment–Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI)

Proteinuria trend versus time for seven patients who achieved remission with adrenocorticotropic hormone (ACTH). Proteinuria trend versus time for seven.

Post-test probabilities of systemic lupus erythematosus (SLE) at different pretest probabilities for a positive and negative cell-bound complement activation.

Suggested treatment algorithm for resistant lupus nephritis

Comparison of the effects of growing podocytes in plasma from patients with lupus nephritis (LN), rheumatoid arthritis or non-renal lupus. Comparison of.

Hierarchical clustering of non-classical monocytes from patients and controls, with tracks indicating individuals, IFN score, SLEDAI score and prednisone.

SLE deconvolution patient clusters and representative immune cell types (A), and distribution of patients by SLE deconvolution cluster and treatment group—all.

Summary of evidence search and selection.

A proposed algorithm for the handling of glucocorticoid (GC) therapy in patients with active or flaring SLE. Mild: presence of only BILAG C or ≤1 BILAG.

Proportion of patients consulting their general practitioner for symptoms within each British Isles Lupus Activity Group (BILAG) domain in the 5 years.

Impact of skin damage on health-related quality of life.

Serum anti-neuronal antibodies (anti-N) in patients with positive serum anti-GRP78. Serum anti-neuronal antibodies (anti-N) in patients with positive serum.

Number of microparticles (MPs) and distribution of MP surface markers in patients with SLE and HCs. Three aliquots of MPs were incubated with (1) anti-CD3,

EULAR Lupus Nephritis Trials Network Study Group

Postulated impact of SLE on endothelial nitric oxide (NO) synthase activity and endothelial nitric oxide synthase (eNOS) uncoupling. Postulated impact.

Mean change from baseline over time in BILAG score,

Overall gene expression in monocyte subsets in patients and controls.

(A) Mean urine protein/creatinine ratio (UPCR) and SEM in participants from the combined Lupus Nephritis Assessment of Rituximab (LUNAR) and A Study to.

IFN-γ-producing T-cells in SLE patients and healthy controls upon EBV antigen stimulation. IFN-γ-producing T-cells in SLE patients and healthy controls.

Activated T-cells in SLE patients and healthy controls upon EBV antigen stimulation. Activated T-cells in SLE patients and healthy controls upon EBV antigen.

Mean serum concentration time profiles of anifrolumab following subcutaneous and intravenous administration of anifrolumab.a aData below the limits of.

The most common pitfalls in lupus clinical trials The inner circle lists the most common pitfalls that have hindered the success of lupus clinical trials.

Median percentage change in complement components 3 and 4 over time by SLE deconvolution cluster—all randomised and treated patients.* *Data from five.

Measures of endothelial activation/dysfunction are associated with QRISK3. Measures of endothelial activation/dysfunction are associated with QRISK3. Increased.

ANCA-Associated Vasculitis: Core Curriculum 2020

Presentation transcript:

Networks of treatment comparisons for primary outcomes of SLE agents in patients with SLE. The size of the nodes (blue circles) corresponds to the number of trials of the treatments. Networks of treatment comparisons for primary outcomes of SLE agents in patients with SLE. The size of the nodes (blue circles) corresponds to the number of trials of the treatments. Comparisons are linked with a line, the thickness of which corresponds to the number of trials that assessed the comparison. +, combined with; AZA, azathioprine; Beli, belimumab; CSA, cyclosporine; CYC-AZA, CYC followed by AZA; CYC, cyclophosphamide; GC, glucocorticoid; HD, high dose; LD, low dose; LEF, leflunomide; MD, moderate dose; MMF, mycophenolate mofetil; MTX, methotrexate; RTX, rituximab; SC, subcutaneous; TAC, tacrolimus. Jingru Tian et al. Lupus Sci Med 2018;5:e000253 ©2018 by Lupus Foundation of America